Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors

Table 2 Selected Trials of Cytotoxic Chemotherapy in Advanced Pancreatic NET

Regimen	Patients	Tumor Response Rate (%)	Median Progression- Free Survival	Median Overall Survival (Months)	Reference
Prospective Studies
Chlorozotocin	33	30	17*	18.0	Moertel et al. 1992 [46]
Fluorouracil + Streptozocin	33	45	14*	16.8	Moertel et al. 1992
Doxorubicin + Streptozocin	36	69	18*	26.4	Moertel et al. 1992
DTIC	50	34	NR	19.3	Ramanathan et al. 2001 [67]
Temozolomide+ Thalidomide	11	45	NR	NR	Kulke et al. 2006 [52]
Temozolomide+ Bevacizumab	17	24	8.6	NR	Kulke et al. 2006 [51]
Temozolomide+ Everolimus	24	35	NR	NR	Kulke et al. 2010 [53]
Retrospective Studies
Steptozocin+ Doxorubicin+ Fluorouracil	84	39	18	37	Kouvaraki et al. 2004 [47]
Temozolomide (diverse regimens)	53	34	13.6	35.3	Kulke et al. 2009 [49]
Temozolomide (single agent)	12	8	NR	NR	Ekeblad et al. 2007 [48]
Temozolomide+ Capecitabine	30	70	18	NR	Strosberg et al. 2010 [50]

ISSN: 1756-8722